Who are Dexmedetomidine Hydrochloride - Cycling's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexmedetomidine 1, Dexmedetomidine load, Brimonidine purite 0.15%, perineural dexmedetomidine, dexmedetomidine 0.25 µg/kg IV, Dexmedetomidine and propofol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-hydrochloride-cycling.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dexmedetomidine Hydrochloride - Cycling — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine Hydrochloride - Cycling (Dexmedetomidine Hydrochloride - Cycling) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Anesthesia/Critical Care.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Anesthesia/Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine Hydrochloride - Cycling (Dexmedetomidine Hydrochloride - Cycling) — Vanderbilt University Medical Center. Dexmedetomidine hydrochloride is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexmedetomidine Hydrochloride - Cycling TARGET	Dexmedetomidine Hydrochloride - Cycling	Vanderbilt University Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Dexmedetomidine 1	Dexmedetomidine 1	National Cancer Institute, Egypt	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine load	Dexmedetomidine load	University of Pennsylvania	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Brimonidine purite 0.15%	Brimonidine purite 0.15%	Northwestern Ophthalmic Institute S.C.	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
perineural dexmedetomidine	perineural dexmedetomidine	Guangzhou Women and Children's Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
dexmedetomidine 0.25 µg/kg IV	dexmedetomidine 0.25 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine and propofol	Dexmedetomidine and propofol	Ain Shams University	marketed	Sedative-hypnotic combination	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine Hydrochloride - Cycling — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-hydrochloride-cycling. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab